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Melanoma: Immunotoxins Targeting Fn14 Receptor
for Malignant Melanoma Treatment
Hong Zhou1, Suhendan Ekmekcioglu2, John W. Marks1, Khalid A. Mohamedali1, Kaushal Asrani3,
Keeley K. Phillips3, Sharron A.N. Brown3, Emily Cheng3, Michele B. Weiss4, Walter N. Hittelman1,
Nhan L. Tran5, Hideo Yagita6, Jeffrey A. Winkles3 and Michael G. Rosenblum1
Fibroblast growth factor-inducible protein 14 (Fn14), the cell surface receptor for tumor necrosis factor-like weak
inducer of apoptosis (TWEAK), is overexpressed in various human solid tumor types and can be a negative
prognostic indicator. We detected Fn14 expression inB60% of the melanoma cell lines we tested, including both
B-Raf WT and B-RafV600E lines. Tumor tissue microarray analysis indicated that Fn14 expression was low in normal
skin, but elevated in 173/190 (92%) of primary melanoma specimens and in 86/150 (58%) of melanoma metastases
tested. We generated both a chemical conjugate composed of the recombinant gelonin (rGel) toxin and the anti-
Fn14 antibody ITEM-4 (designated ITEM4-rGel) and a humanized, dimeric single-chain antibody of ITEM-4 fused
to rGel (designated hSGZ). Both ITEM4-rGel and hSGZ were highly cytotoxic to a panel of different melanoma
cell lines. Mechanistic studies showed that both immunotoxins induced melanoma cell necrosis. In addition,
these immunotoxins could upregulate the cellular expression of Fn14 and trigger cell-signaling events similar to
the Fn14 ligand TWEAK. Finally, treatment of mice bearing human melanoma MDA-MB-435 xenografts with either
ITEM4-rGel or hSGZ showed significant tumor growth inhibition compared with controls. We conclude that Fn14
is a therapeutic target in melanoma and the hSGZ construct appears to warrant further development as a
therapeutic agent against Fn14-positive melanoma.
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INTRODUCTION
Metastatic melanoma has a poor prognosis, with the median
survival for patients with stage IV disease ranging from 8 to 18
months (Balch et al., 2009). The standard treatment regimens
(DTIC or IL-2) provide only 15–25% response rates (Tsao
et al., 2004). Recently, ipilimumab, an antibody to cytotoxic
T-lymphocyte antigen-4 (Sondak et al., 2011), and the
B-RAFV600E inhibitor vemurafenib (Flaherty et al., 2011)
were approved by the Food and Drug Administration for
treatment of unresectable or metastatic melanoma. Although
there are a number of new agents and strategies under
development, few achieve greater response rates (Hocker
et al., 2008; Ascierto et al., 2010). An effective treatment
strategy for advanced melanoma thus remains a critical
imperative.
Tumor necrosis factor (TNF)-like weak inducer of apoptosis
(TWEAK) and fibroblast growth factor-inducible protein 14
(Fn14) are a TNF superfamily ligand–receptor pair involved in
inflammation, oncogenesis, tumor invasion, migration, survi-
val, and resistance to chemotherapy (Burkly et al., 2007;
Winkles, 2008). Fn14 is expressed at relatively low levels in
normal tissues, but is markedly elevated locally in injured
tissues, where it has a role in tissue remodeling (Winkles,
2008). In addition, Fn14 is highly expressed in breast (Willis
et al., 2008) and brain (Tran et al., 2006) tumors, and appears
to have a role in the invasive potential of those diseases. The
Fn14 gene has been shown to be overexpressed in numerous
other tumor types (Culp et al., 2010). The correlation between
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increased Fn14 expression and higher tumor grade and/or
poor prognosis has been documented in brain (Tran et al.,
2003, 2006), breast (Willis et al., 2008), esophageal (Wang
et al., 2006; Watts et al., 2007), prostate (Huang et al., 2011),
gastric (Kwon et al., 2012), and bladder (Als et al., 2007)
cancer.
The functional relevance of this pathway in oncology
suggests that an agent targeted to this pathway might be a
potent cancer therapeutic (Winkles, 2008; Michaelson and
Burkly, 2009). Several approaches targeting Fn14 in
preclinical models have been explored (Culp et al., 2010;
Michaelson et al., 2011; Zhou et al., 2011). We previously
reported that the antibody–toxin conjugate ITEM4-rGel target-
ing Fn14 showed significant growth-inhibiting effects against
numerous tumor cell lines in vitro and long-term growth
suppression in a human bladder tumor xenograft model (Zhou
et al., 2011). These studies suggest that therapeutic targeting
of the TWEAK/Fn14 pathway in cancer patients may inhibit
tumor growth.
rGel is a type I ribosome–inactivating toxin lacking the
ability to efficiently bind to the cell surface or internalize into
mammalian cells (Rosenblum et al., 1995), making this an
excellent payload for targeted therapy approaches. Phase 1
clinical studies of an rGel immunoconjugate containing the
anti-CD33 antibody HuM195 have shown limited antigenicity
and no vascular leak issues with rGel even after repeated
administration (Borthakur, Rosenblum, et al, submitted for
publication). For this study, we further characterized the
properties of the ITEM4-rGel conjugate described previously
(Zhou et al., 2011) and generated a new construct consisting
of a humanized, dimeric single-chain antibody of ITEM-4
fused to rGel (designated hSGZ). Here we also present tissue
microarray (TMA) immunohistochemistry (IHC) data which
identifies Fn14 as a potential therapeutic target for melanoma.
In addition, we evaluated the cytotoxic efficacy of the ITEM4-
rGel and hSGZ immunotoxins against a panel of melanoma
cell lines in vitro and against MDA-MB-435 melanoma cells
in vivo.
RESULTS
Fn14 expression in melanoma cell lines and tumors
Fn14 expression was not detected in normal melanocytes, but
it was detected in 20 of 23 melanoma cell lines tested,
regardless of the tumor stage that the melanoma lines represent
(Figure 1a). The B-Raf kinase has been shown to represent an
important target in melanoma (Davies et al., 2002; Curtin
et al., 2005). Fn14 expression appeared to be independent of
B-Raf gene status in this panel of melanoma cell lines
(Figure 1a). We then examined a microarray composed of 40
human melanoma cell lines by IHC (Supplementary Table S1
online). Compared with the normal human epidermal mela-
nocyte line NHEM-2311, Fn14 was found to be overexpressed
inB60% of the lines tested. The intensity of protein expression
was slightly higher in the cell lines representing the radial
growth phase. Representative images from the melanoma cell
line microarray staining are shown in Figure 1b. Fn14 expres-
sion on the melanoma cell surface was confirmed using flow
cytometry (Supplementary Figure S1 online).
We next investigated Fn14 protein expression levels using
IHC analysis on a melanoma progression tumor TMA, con-
sisting of 462 tissue cores assembled to reflect samples of
tumors from each step in melanocytic tumor progression. A
semiquantitative scoring system of 0 to 3 for the expression
levels of protein was used to reflect the staining intensity in
tumor cells as illustrated in Figure 1c. As shown in Table 1,
173/190 (92%) of primary melanoma specimens and 86/150
(58%) of melanoma metastases specimens scored positive for
Fn14. Interestingly, Fn14 expression was also detected in
benign nevi and was elevated in 103/122 (84%) of these
samples (Table 1). There was no significant difference
between individual tumor stages for Fn14 expression in this
TMA. Importantly, only 19% (87/462) of the melanoma
samples were negative for Fn14 expression. Fn14 expression,
presented here, was scored exclusively for the tumor cell
protein expression rather than stroma or immune cells residing
in the tumor environment. In addition, we did not detect Fn14
staining in primary melanocytes or tissue samples.
Immunotoxin construction, expression, and purification
We modeled a single-chain version of the ITEM4-rGel
immunotoxin (Zhou et al., 2011) by isolating RNA from
hybridoma cells expressing the ITEM-4 antibody, preparing
complementary DNA, and amplifying the complementary
DNA-encoding murine IgG VH and VL regions. The VH and
VL domains were tethered by a flexible 218 linker (Whitlow
et al., 1993) to produce scFv fragments in either VH–VL or
VL–VH orientations. The initial rGel-based immunotoxins
consisted of a flexible L linker (GGGGS) tethering the
COOH terminus of scFvIT4 or hscFvIT4 to the native rGel
NH2 terminus. To determine whether the relative orientation
of VH and VL domains affected the cytotoxic effect on Fn14-
expressing tumor cells, the monovalent immunotoxins were
constructed with VH–VL and VL–VH formats. To develop Fn14-
targeted immunotoxins more suitable for clinical use, a
humanized single-chain version of ITEM-4 (designated
hscFvIT4, Supplementary Figure S2 online) specific for Fn14
was successfully produced and characterized. Using hscFvIT4
and rGel toxin, we next engineered a bivalent immunotoxin
(hSGZ) by adding a COOH-terminal dimerization domain
(bZIP) (Carrillo et al., 2010). Illustrations of the immunotoxin
constructs are shown in Figure 2a. Following purification, all
the rGel-based immunotoxins migrated on SDS-PAGE at the
expected molecular weights of B55 kDa for monovalent
immunotoxins and B120 kDa for bivalent immunotoxin
(Figure 2b).
Binding of immunotoxins to Fn14
The binding of ITEM-4, scFvs, and immunotoxins to recombi-
nant Fn14 extracellular domain was assessed by surface
plasmon resonance (BIAcore) analysis. We found that ITEM-
4, scFvIT4, and hscFvIT4 bound to Fn14 with similar equili-
brium dissociation constants (Kds) of B1.14, 1.19, and
6.25 nmol l1, respectively (Figure 2c). The immunotoxins
ITEM4-rGel, scFvIT4/rGel (VH–VL), scFvIT4/rGel (VL–VH),
hSGZ (monomer), and hSGZ (dimer) bound to Fn14 with
equilibrium dissociation constants (Kds) of 2.5, 1.08, 2.3, 2.5,
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and 1.4 nmol l1, respectively (Figure 2c). Purified rGel did
not bind to Fn14 in this assay. Both immunotoxins showed
specific binding to MDA-MB-435 cells compared with the
background of binding to Fn14-deficient mouse embryonic
fibroblasts (MEF 3.5 / ) in an ELISA-based binding assay
(Supplementary Figure S3A online).
Conversion into a bivalent format improves the cytotoxic effects
of scFvIT4/rGel
We investigated whether ITEM4-rGel and the scFvIT4/rGel-
based fusion proteins had similar cytotoxicity against various
melanoma cell lines. To quantitatively compare the cytotoxi-
city of bivalent and monovalent formats, dose-dependent
growth inhibition curves were established on MDA-MB-435
cells (Figure 2d). An IC50 value of 0.006 nmol l
 1 was
obtained for ITEM4-rGel. IC50 values of 12.0, 3.6, and
18.3 nmol l1 were obtained for scFvIT4/rGel (VH–VL),
scFvIT4/rGel (VL–VH) (Figure 2d), and hSGZ (monomer)
(Supplementary Figure S3B online), respectively. An IC50
value of 0.008 nmol l 1 was calculated for hSGZ dimer
(Figure 2d and Supplementary Figure S3B online). Thus, a
2287-fold reduction in IC50 value was achieved by converting
monomeric hSGZ into homodimeric, bivalent hSGZ. Unless
otherwise specified, hSGZ refers to the dimeric construct.
ITEM4-rGel and hSGZ demonstrated significant cytotoxicity
against melanoma cell lines (IC50 ranged from 0.1 pmol l
 1 to
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Figure 1. Fibroblast growth factor-inducible protein 14 (Fn14) is overexpressed in melanoma cell lines and human tumor samples. (a) Cell lines were assayed for
Fn14 and tubulin levels by western blot analysis. B-RAF status is indicated: WT, wild-type; MT, V600 mutant; RGP, radial growth phase; VGP, vertical growth
phase. (b) Fn14 expression in melanoma cell lines was also assayed using a cell line microarray and an anti-Fn14 antibody. Images from four of the lines are
shown. Bar¼100mm. (c) Paraffin sections of melanocytic tumor progression tissue microarray were immunostained with an anti-Fn14 antibody. A relative staining
intensity (0–3þ ) was assigned and a melanoma specimen representing each intensity level is presented. Bar¼100mm.
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1.1 nmol l1) and they were 2.2- to 2.8105-fold
more potent than free rGel (Supplementary Table S2 online).
By comparison, the cytotoxic effects of these immunotoxins
on Fn14-negative MEF3.5 / cells was similar to that of free
rGel (Supplementary Table S2 online). As shown in Figure 2e,
preincubation with 1mmol l1 ITEM-4 for 4 hours shifted the
ITEM4-rGel and hSGZ-induced cytotoxicity to that of the rGel
curve in WM35 cells.
Cellular uptake of immunotoxins
Immunofluorescence staining was done on MDA-MB-435 and
MEF 3.5 / cells after exposure to the immunotoxins. As
shown in Figure 2f, the rGel moiety (green) of both immuno-
toxins was observed primarily in the cytosol of MDA-MB-435
cells. Internalization did not occur in MEF 3.5 / cells (data
not shown).
Mechanistic studies of immunotoxin cytotoxic effects
Immunotoxins did not induce apoptosis or autophagy when
added to Fn14-positive melanoma cells (Supplementary Figure
S4 online). To assess whether necrotic cell death was induced,
we performed a propidium iodide exclusion assay, which
investigates the early loss of plasma membrane integrity that
occurs during classical necrosis (Do et al., 2003). MDA-MB-
435 and AAB-527 cells displayed an increasing loss of plasma
membrane integrity after treatment with ITEM4-rGel or hSGZ
but not treatment with ITEM-4 or rGel (Figure 3a). In contrast,
immunotoxins did not induce necrosis when added to
MEF3.5 / cells (Supplementary Figure S4C online). For
further confirmation of a necrotic response, the lactate
dehydrogenase (LDH) release assay was used to measure cell
lysis (Do et al., 2003). Immunotoxin-induced LDH release was
found to be both time- and dose-dependent for both cell lines
studied; however, treatment with ITEM-4 and rGel did not
induce LDH release in this assay (Figure 3b).
A common event in numerous forms of cell death is
mitochondrial outer membrane permeabilization, which
results in escape of mitochondrial proteins that are toxic
within the cytosol, then a rapid decline in ATP production,
and the generation of reactive oxygen species (Kroemer and
Martin, 2005). We also found that exposure of MDA-MB-435
and AAB-527 cells to ITEM4-rGel and hSGZ but not ITEM-4 or
rGel resulted in mitochondrial membrane depolarization
using the mitochondrial dye JC-1 (Figure 3c). This finding
indicates that the immunotoxins may promote reactive oxygen
species release, which could contribute to cell death induced
by these constructs.
The ITEM-4 antibody and derivative immunotoxins can
upregulate Fn14 expression and activate the NF-jB pathway
It has been reported that TWEAK treatment of human glioma
(Tran et al., 2006) and prostate (Huang et al., 2011) tumor
cells increases Fn14 gene expression. As ITEM-4 has agonistic
activity (Nakayama et al., 2003), we considered the possibility
that the ITEM4-based immunotoxins might actually increase
the expression of their cell surface target. ITEM-4 treatment
increased Fn14 expression in all cell lines tested (Figure 4a
and Supplementary Figure S5A and B online). As Fn14 is an
NF-kB target gene (Tran et al., 2006), we tested whether
ITEM-4 could activate the NF-kB pathway using a HEK293/
NFkB-luc/Fn14 luciferase reporter cell line. ITEM-4, but not
isotype-matched control IgG, dose dependently resulted in the
induction of the NF-kB pathway reporter gene (Figure 4b).
Consistent with this data, we found that ITEM4-rGel and hSGZ
can induce both the classical (not shown) and alternative
NF-kB signaling pathways as well as Fn14 expression after
treatment of MDA-MB-435 cells (Figure 4c and d) and
AAB-527 cells (Supplementary Figure S5C online), similar to
the effect observed upon treatment with ITEM-4 and TWEAK.
We also detected increased Fn14 levels on the melanoma cell
surface after immunotoxin treatment (Supplementary Figure
S5E online). Finally, ITEM4-rGel and hSGZ can also induce
expression of additional NF-kB-regulated genes, including IL-8
and TNF-a (Supplementary Figure S5D online). Taken
together, the data indicate that the ITEM4-rGel and hSGZ
exhibit agonistic activity, including activation of the NF-kB
signaling pathway and induction of Fn14, IL-8, and TNF-a
production, analogous to the effects of TWEAK.
hSGZ exhibited comparative in vivo tumor growth inhibition
activity to ITEM4-rGel
We next examined the effect of immunotoxins on the growth
of established human melanoma (MDA-MB-435-Luc) xeno-
grafts assessed by either caliper measurement or biolumines-
cence imaging (BLI). Significant tumor growth inhibition was
observed at doses of 30 or 60 mg kg1 of the ITEM4-rGel
(Figure 5a and Supplementary Figure S6B online) and 25 or
50 mg kg1 of the hSGZ construct (Figure 5b and
Supplementary Figure S6D online) compared with saline-
treated controls (Po0.005). Mice treated with 60 mg kg 1
ITEM-4 also had less tumor growth relative to the saline
Table 1. Summary of the immunostaining of Fn14
across 462 samples from 169 patients with melanoma
IHC score
Specimen 0 1þ 2þ 3þ X2þ Percentage
Nevus 84
Thin 4 1 9 21 30/35
Thick 7 7 38 35 73/87
Primary 92
Thin 4 1 24 42 66/71
Thick 9 3 50 57 107/119
Metastases 58
Lymph node 25 0 3 32 35/60
Visceral 38 1 7 44 51/90
Abbreviations: Fn14, fibroblast growth factor-inducible protein 14;
IHC, immunohistochemistry.
Notes: IHC score is based on the percentage of epithelial cells stained in
the tumor portion of the sample: ‘‘0,’’ o5% positive cells; ‘‘1,’’ 5–25%
positive cells; ‘‘2,’’ 425–75% positive cells; and ‘‘3,’’ 475% positive
cells. Thin refers to lesions o1 mm and thick refers to lesions 41 mm.
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control; however, this difference bordered on statistical
significance (P¼ 0.049). The representative BLI images of the
tumors on selected days clearly demonstrated the antitumor
properties of the ITEM4-rGel (Supplementary Figure S6A
online) and hSGZ (Figure 5c). We also found that hSGZ
treatment upregulated Fn14 expression in vivo as assayed by
western blot analysis of tumor tissues (Figure 5d). Immuno-
fluorescence staining confirmed that ITEM4-rGel and hSGZ
localized specifically in tumor tissue, and no nonspecific
staining was observed in tumors after administration of
ITEM-4 and saline detected by anti-rGel antibody
(Figure 5e). This suggests that the ITEM4-rGel and hSGZ can
target tumor cells overexpressing Fn14 in vivo. Toxicity was
monitored by frequent body weight measurements in groups
of mice treated with ITEM4-rGel or hSGZ. Body weights
showed less than a 20% change in any of the treated
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Figure 2. Characterization of immunotoxins targeting the fibroblast growth factor-inducible protein 14 (Fn14) receptor. (a) Schematic diagram of immunotoxin
constructs containing scFvIT4 and hscFvIT4, peptide linker (218 and L), recombinant gelonin (rGel) toxin, and bZIP dimerization domain. The amino-acid
sequence of the linker and bZIP domain is shown. (b) SDS-PAGE analysis of purified scFvIT4 and immunotoxins in nonreducing conditions. (c) Surface plasmon
resonance analysis of scFvIT4, hscFvIT4, ITEM-4, and immunotoxins binding to recombinant Fn14 extracellular domain. (d) Various concentrations of rGel, ITEM4-
rGel, two different formats of fusion immunotoxins, and bivalent format of hSGZ were added to MDA-MB-435 cells, and cytotoxicity was measured as described
in Materials and Methods. (e) Pretreatment of WM35 cells with ITEM-4 abrogated the cytotoxic effects of ITEM4-rGel and hSGZ. (f) Internalization of ITEM4-rGel
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Figure 3. Cell death induced by ITEM4-rGel and hSGZ resembles necrosis. (a) Propidium iodide (PI) exclusion assay for ITEM4-rGel and hSGZ after 24 or
48 hours of exposure in MDA-MB-435 and AAB-527 cells, respectively. The percentage of cells with PI staining is indicated within each panel. (b) Lactate
dehydrogenase (LDH) release assay for ITEM4-rGel and hSGZ after 24 and 48 hours of treatment in MDA-MB-435 and AAB-527 cells, respectively. Results
represent mean±SD, n¼3. (c) MDA-MB-435 and AAB527 cells were either left untreated or treated with 1 nmol l1 ITEM-4, ITEM4-rGel, or hSGZ for 48 hours
and then mitochondrial membrane depolarization was assayed by JC-1 staining followed by flow cytometric analysis. Numbers in the lower right quadrants,
percentage of cells with JC-1 green fluorescence; rGel, recombinant gelonin.
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mice over the duration of the experiment for ITEM4-rGel
(Supplementary Figure S6C online) and hSGZ (Supplementary
Figure S6E online) administration.
DISCUSSION
This study identifies Fn14 as a potential new target for
melanoma therapy. We first explored the expression charac-
teristics of Fn14 in a large set of melanoma cell lines
representing various stages of disease progression. Our results
showed that although the increased expression of Fn14 in
melanoma cell lines is suggestive of a link to melanoma, even
more notable is that in some melanoma cell lines (such as
WM35 P1.N1 and WM35 P2.N1) there appears to be a link
between Fn14 expression and tumor progression. Nevi may
further progress to melanoma or can regress by differentiating
to cell types that have been histopathologically defined
as (nonmalignant) Schwann cells (Clark Jr et al., 1984).
Interestingly, Fn14 was expressed at a similar frequency in
benign nevi and in primary melanomas, but with a lower
frequency in metastatic melanomas, suggesting that it is
upregulated in early melanoma tumorigenesis. The high
percentage of Fn14 expression in melanoma prompted us to
develop the Fn14-targeted immunotoxins as antimelanoma
therapeutic agents.
We constructed different formats of immunotoxins and all of
them showed high binding to Fn14. The conversion of
monovalent hSGZ immunotoxin into a bivalent format by
adding a COOH-terminal dimerization domain markedly
enhanced the potency of this construct in vitro (Figure 2d
and Supplementary Figure S3B online), suggesting an effect of
higher-order cross-linking of Fn14 molecules on the cell
surface induced by bivalent binding.
Cell death caused by Fn14-targeted immunotoxins could be
the result of a combination of activation of the intrinsic
cytotoxicity related to the Fn14 pathway (Michaelson and
Burkly, 2009) and the inhibition of protein synthesis by the
rGel toxin. We previously demonstrated that the ITEM4-rGel
immunotoxin killed T-24 bladder tumor cells through an
apoptotic mechanism with the release of HMGB1 protein
(Zhou et al., 2011). However, the cytotoxic effects of ITEM4-
rGel and hSGZ on melanoma cells occurred through a cellular
necrosis mechanism and involved LDH release. Taken
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together, these data suggest that Fn14-targeted immunotoxins
can induce cell death through different mechanisms and the
effects appear to be cell type-dependent. The necrotic cell
death mechanism observed after melanoma cell exposure to
the Fn14-targeted immunotoxins may also be the result of the
well-known intrinsic resistance of these cells to apoptosis
(Soengas and Lowe, 2003).
In general, the efficacy of antibody-based therapies can be
hampered as the tumor cells adopt defensive tactics, such as
shedding of the target antigen/receptor and masking to escape
immune surveillance. Target antigen/receptor expression may
also be downregulated in vivo because of therapy with other
agents. We found that the Fn14 expression was upregulated by
ITEM-4 treatment. This effect was also observed with the
natural Fn14 ligand TWEAK and the immunotoxins. Consistent
with our in vitro results, Fn14 expression in xenograft tumors
was upregulated by hSGZ administration (Figure 5d). We also
showed that, like TWEAK, Fn14-targeted immunotoxins are
capable of inducing NF-kB pathway activation. Signaling
by the TWEAK/Fn14 axis appears to exert either protumori-
genic or antitumorigenic effects depending on the particular
microenvironment (Winkles, 2008; Michaelson and Burkly,
2009). It is important to note that no enhancement in tumor
growth was observed following ITEM-4 treatment in our
xenograft models. This result is consistent with prior data
indicating that the administration of TWEAK resulted in
marked reduction in tumor growth in xenograft models
(Michaelson et al., 2011). ITEM4-rGel was found to be
slightly more potent than hSGZ in the xenograft model
(Figure 5a and b, ITEM4-rGel 30 mg kg1 treated group versus
hSGZ 50 mg kg 1 treated group). The better potency observed
with ITEM4-rGel could be because of the longer half-life of the
larger IgG conjugate in vivo (Zalevsky et al., 2010), antibody-
dependent cellular cytotoxicity (ADCC) of ITEM-4 (Nakayama
et al., 2003), and a more efficient agonistic activity of the IgG
construct in this specific setting. Given the cross-species
reactivity of ITEM-4 to mouse Fn14, the toxicity of ITEM4-
rGel or hSGZ on nontumor tissues in vivo was found to be
minimal and this may be reflective of expected toxicity in
patients.
The abundant overexpression of Fn14 in melanoma makes
it an attractive cell surface target for agents, such as immuno-
toxins. hSGZ, the humanized counterpart of ITEM4-rGel, has a
unique cytotoxicity to melanoma and these findings, together
with its in vivo antitumor efficacy, suggest that hSGZ warrants
further development as a therapeutic agent against Fn14-
positive melanoma.
MATERIALS AND METHODS
Cell lines and reagents
Human melanoma cell lines (WM3211, Sbcl2, WM1346, WM1361A,
WM1366, WM793, WM983A, MeWo, WM46, A375, WM983B, SK-
MEL-3, SK-MEL-24, SK-MEL-28, SK-MEL-32, WM35, WM35P2N1,
SB2, SK-MEL-1, and SK-MEL-5) were maintained in RPMI 1640
medium (HyClone, Logan, UT). Melanoma cell lines, A375M, AAB-
527, and Fn14-deficient MEFs (MEF 3.5 / ), were maintained in
DMEM (HyClone). All medium contained 10% fetal bovine serum.
The luciferase-expressing human melanoma cell line MDA-MB-435-
Luc was derived from MDA-MB-435 cells as previously reported
(Murray et al., 2003). The murine IgG2b/k mAb ITEM-4 directed
against human and mouse Fn14 receptor (Nakayama et al., 2003) and
the generation of immunoconjugate ITEM4-rGel have been described
previously (Zhou et al., 2011). Recombinant human TWEAK was
purchased from R&D Systems (Minneapolis, MN).
Melanoma cell line microarray, TMA, and IHC
A human melanoma cell line microarray was established at M.D.
Anderson Cancer Center (MDACC). The melanocytic tumor progres-
sion TMA was designed to provide samples of tumors from each step
in melanocytic tumor progression (Nazarian et al., 2010). The TMA
contains 462 tissue cores from 169 patients, consisting of benign nevi
(122 cores from 35 patients), primary cutaneous melanomas (190
cores from 59 patients), melanoma metastases to lymph nodes (60
cores from 29 patients), and melanoma metastases to visceral organs
(90 cores from 46 patients). Acral, mucosal, and uveal melanomas
were excluded from this TMA (Nazarian et al., 2010).
Immunohistochemical analysis for Fn14 was performed as
previously described using 2.5mg ml 1 of the Fn14 mAb P4A8 and
an isotype-matched murine IgG as control (Tran et al., 2003).
Immunolabeling was scored separately for two variables: first, for
number of positive melanoma cells; and second, for the overall
intensity of immunoreactivity of the positive cells. Scoring for number
of positive tumor cells was defined as follows: 0,o5% positive cells;
1, 5–25% positive cells; 2, 425–75% positive cells; and 3, 475%
positive cells. Intensity scoring was defined as follows: 0, no staining;
1, light staining; 2, moderate staining; and 3, intense staining. The
slides were independently interpreted by two readers without knowl-
edge of the clinical data. Any discrepancies in scores were subse-
quently reconciled.
In vitro studies
The following methods are described in Supplementary Materials and
Methods online: cloning and humanization of single-chain Fv (scFv);
plasmid construction; protein expression in Escherichia coli; isolation
and purification of fusion immunotoxins; surface plasmon resonance
assay (Brown et al., 2006); ELISA (Cao et al., 2009) and
internalization analyses (Zhou et al., 2011); reticulocyte lysate
in vitro translation assay (Hale, 2001); in vitro cytotoxicity assay
(Zhou et al., 2011); flow cytometry analysis (Zhou et al., 2011);
propidium iodide exclusion assay (Do et al., 2003); LDH release
assay; mitochondrial membrane depolarization assay; apoptosis
assay; western blot analysis; and the NF-kB pathway luciferase
reporter assay (Brown et al., 2010).
In vivo efficacy studies
Animal procedures were conducted according to a protocol approved
by the AALAC-approved Animal Care and Use Facility at MDACC.
Female BALB/c nude mice (Harlan Sprague Dawley, Indianapolis,
IN), 8 weeks old, were injected (hind flank) subcutaneously with
MDA-MB-435-LUC cells (1 107 cells per mouse; suspended in
100ml of phosphate-buffered saline mixed with 100ml BD Matrigel,
San Jose, CA). Once tumors reached a mean volume of B200 mm3,
animals (five mice per group) were treated (intravenously via tail vein)
with phosphate-buffered saline, ITEM-4, or with immunotoxins.
Animals were monitored and tumors were measured every 2–3 days.
Data are presented as mean tumor volume (mm3)±SD.
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BLI
In vivo BLI was conducted using the IVIS100 system with Living
Image acquisition and analysis software (Caliper Life Sciences,
Hopkinton, MA). Anesthetized mice were intraperitoneally injected
with 75 mg kg 1 D-luciferin (Gold Biotechnology, St Louis, MO) and
imaged for 10 minutes after luciferin injection.
Localization of ITEM4-rGel and hSGZ in tumor tissue
Twenty-four hours after intravenous injection of ITEM-4, ITEM4-rGel,
or hSGZ, mice were killed and tumor samples were collected and
frozen immediately for sectioning. Localization of ITEM4-rGel and
hSGZ in tumor tissues was assessed as previously described (Zhou
et al., 2011).
Statistical analysis
A number of statistical methods were employed for the analysis of the
microarray data. Cohen’s Kappa coefficient was estimated to assess
the degree of agreement between duplicate readings for the same
sample. In addition, Bowker’s test of symmetry was applied to the
analyses. To determine the relationship between Fn14 readings and
disease stages, the Fn14 percentages or intensity scores were treated
as ordinal responses and an ordinal regression model accounting for
repeated measurements within each sample was used to fit the Fn14
scores. All computations, including w2 tests, were performed in SAS
v9.2 (SAS Institute Inc. Cary, NC). P-values were obtained using
one-tailed t-test with 95% confidence interval for evaluation of the
statistical significance compared with the controls in the animal
studies. Po0.05 was considered statistically significant.
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